CY
CYDX.US Cyduct Diagnostics Inc
- Market cap
- USD 11.7M
- P/E
- 1.2x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CYDX.US undervalued?
Graham numberThe Graham number of Cyduct Diagnostics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cyduct Diagnostics Inc fundamental analysis
No fundamental analysis for Cyduct Diagnostics Inc yet.
Cyduct Diagnostics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cyduct Diagnostics Inc
CYduct Diagnostics, Inc., a healthcare company, develops, produces, and markets medical devices for the assessment, identification, diagnosis and treatment of breast cancer. The company offers HALO system, a noninvasive device that utilizes proprietary technology to obtain breast fluid; and MammoView, a fiberoptic technology with the ability to view and collect cells and other abnormalities. It also provides women and clinicians with technology that will lead the Intraductal…
Full company profileCyduct Diagnostics Inc financial statements
Cyduct Diagnostics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 263K | 232K | 184K | 194K | 161K | 94.1K | 119K | 84.5K | 70.7K | 70.4K |
| Gross Profit | 153K | 135K | 92.8K | 132K | 116K | 63.5K | 83.4K | 56.6K | 46.8K | 43.9K |
| Operating Income | -318K | -186K | -287K | -249K | -371K | -404K | -445K | -379K | -363K | -155K |
| EBITDA | -1.48M | -617K | 1.92M | 732K | -371K | -167K | -441K | -379K | -363K | -155K |
| Net Income | -1.48M | -617K | 1.92M | 559K | -372K | -420K | -473K | -418K | -414K | -207K |
| EPS | -5.32 | -1.31 | 3.14 | 0.19 | -0.07 | -0.08 | -0.09 | -0.08 | -0.08 | -0.04 |
| Balance Sheet | ||||||||||
| Total Assets | 1.21M | 155K | 126K | 102K | 71.5K | 297K | 80.8K | 54.7K | 37.7K | 30.0K |
| Total Liabilities | 3.92M | 3.34M | 1.44M | 855K | 1.20M | 1.85M | 2.10M | 2.45M | 2.85M | 1.09M |
| Shareholders' Equity | -2.71M | -3.18M | -1.31M | -753K | -1.13M | -1.55M | -2.02M | -2.40M | -2.81M | -1.06M |
| Cash & Short-term Investments | 1.59K | 9.60K | 30.6K | 18.4K | 18.9K | 272K | 54.8K | 29.8K | 1.21K | 7.22K |
| Total Debt | 25.3K | - | 80.0K | 80.0K | 140K | 520K | 570K | 670K | 713K | 708K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -58.6K | 8.02K | -11.5K | -12.2K | -57.9K | -128K | -267K | -175K | -72.0K | 11.5K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 4.00 | 3.00 | 0.00 | 5.00 |
| Free Cash Flow | -58.6K | 8.02K | -11.5K | -12.2K | -57.9K | -128K | -267K | -175K | -72.0K | 11.5K |
| Ratios | ||||||||||
| ROA | -121.9% | -397.5% | 1,515.6% | 546.1% | -520.5% | -141.7% | -584.7% | -763.6% | -1,097.7% | -690.9% |
| Net Profit Margin | -562.6% | -265.9% | 1,039.3% | 287.5% | -231.3% | -447.1% | -396.1% | -494.8% | -585.1% | -294.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cyduct Diagnostics Inc dividends
Cyduct Diagnostics Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:250 on Dec 1, 2020.
Who owns Cyduct Diagnostics Inc
Ownership data of Cyduct Diagnostics Inc is not available yet.
Cyduct Diagnostics Inc company profile
- Company name
- Cyduct Diagnostics Inc
- Ticker
- CYDX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3
- Fiscal year end
- June
- Address
- 1698 Post Rd. E, Westport, CT, United States, 06880
- Phone
- 888-545-9112
- Website
- cyductdx.com
About Cyduct Diagnostics Inc
CYduct Diagnostics, Inc., a healthcare company, develops, produces, and markets medical devices for the assessment, identification, diagnosis and treatment of breast cancer. The company offers HALO system, a noninvasive device that utilizes proprietary technology to obtain breast fluid; and MammoView, a fiberoptic technology with the ability to view and collect cells and other abnormalities. It also provides women and clinicians with technology that will lead the Intraductal approach to breast cancer and improvement in breast healthcare. The company was formerly known as Solos Endoscopy, Inc. and changed its name to CYduct Diagnostics, Inc. in December 2020. CYduct Diagnostics, Inc. was incorporated in 1986 and is based in Westport, Connecticut.
Cyduct Diagnostics Inc management
3- Mr. Dom L. GattoPresident, CEO, Secretary, Treasurer & Chairman · born 1962
- Mr. Fred V. Schiemann CPACFO & Director · born 1952
- Mr. Gerald SchwebelOperations Manager